# A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

> **NCT06566742** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
- Clonal Cytopenia of Undetermined Significance

## Interventions

- **DRUG:** Olutasidenib

## Key facts

- **NCT ID:** NCT06566742
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-10
- **Primary completion:** 2027-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06566742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06566742, "A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06566742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*